What are Anti-VEGF agent drugs?

Anti-VEGF agent drugs are pharmacologic agents that share a common mechanism (typically targeting VEGF-A (and VEGF-B for aflibercept)). 3 are currently marketed, with 5 more in clinical development.

What are the marketed Anti-VEGF agent drugs?

Marketed Anti-VEGF agent drugs include Aflibercept and ranibizumab, Ranibizumab and Aflibercept, Primary Medical Treatment Pathway.

Anti-VEGF agent

3 marketed 4 in Phase 3 1 in Phase 2

This page covers all Anti-VEGF agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF-A (and VEGF-B for aflibercept), VEGF-A (vascular endothelial growth factor-A), VEGF.

Targets

VEGF-A (and VEGF-B for aflibercept) · VEGF-A (vascular endothelial growth factor-A) · VEGF · VEGF-A

Marketed (3)

Aflibercept and ranibizumab · Instituto de Olhos de Goiania · Ophthalmology
Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.
Ranibizumab and Aflibercept · Instituto de Olhos de Goiania · Ophthalmology
Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.
Primary Medical Treatment Pathway · Moorfields Eye Hospital NHS Foundation Trust · Ophthalmology
This drug works by inhibiting the action of vascular endothelial growth factor (VEGF) to reduce angiogenesis.

Phase 3 pipeline (4)

Sham to ranibizumab · Novartis · Ophthalmology
Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.
intravitreal ranibizumab & photodynamic therapy · University Hospital, Basel, Switzerland · Ophthalmology
Intravitreal ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor, reducing angiogenesis and edema in the retina.
Ranibizumab + deferred laser · Jaeb Center for Health Research · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor.
ranibizumab intravitreal injection · Hawaii Pacific Health · Ophthalmology
Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

Phase 2 pipeline (1)

Avacincaptad Pegol intravitreal solution · ONL Therapeutics · Ophthalmology
Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.